MCLAUGHLIN KEVIN F
MCLAUGHLIN KEVIN F's purchase track record
MCLAUGHLIN KEVIN F has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/19/2025 | IVVD | $125K | -34.0% | -56.4% | +11.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
IVVD noted among health-care stocks moving on Monday. Invivyd (IVVD) was listed among twelve health-care stocks that showed price movement in Monday’s pre-market and intraday sessions, according to Benzinga. The mention reflects short-term trading activity but does not indicate a specific catalyst for the company.
Transaction History
| VCEL | ▼ Sell | Open Market | 7,000 | $312K | 8/12/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 7,000 | $91K | 8/12/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,500 | $9K | 5/13/2026 | View on chart |
| VCEL | ▼ Sell | Open Market | 3,500 | $115K | 5/13/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,500 | $46K | 5/13/2026 | View on chart |
| VCEL | ▼ Sell | Open Market | 3,500 | $115K | 5/13/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,200 | — | 4/29/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 7,000 | $18K | 2/11/2026 | View on chart |
| VCEL | ▼ Sell | Open Market | 7,000 | $243K | 2/11/2026 | View on chart |
| IVVD | ▲ Buy | Open Market | 50,000 | $125K | 11/19/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 7,000 | $18K | 11/10/2025 | View on chart |
| VCEL | ▼ Sell | Open Market | 7,000 | $270K | 11/10/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 7,000 | $19K | 8/6/2025 | View on chart |
| VCEL | ▼ Sell | Open Market | 7,000 | $251K | 8/6/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 7,000 | $19K | 5/7/2025 | View on chart |
| VCEL | ▼ Sell | Open Market | 7,000 | $280K | 5/7/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,200 | — | 4/30/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 6,000 | $22K | 2/12/2025 | View on chart |
| VCEL | ▼ Sell | Open Market | 6,000 | $333K | 2/12/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,000 | $3K | 2/12/2025 | View on chart |
| VCEL | ▼ Sell | Open Market | 1,000 | $55K | 2/12/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 7,000 | $26K | 11/13/2024 | View on chart |
| VCEL | ▼ Sell | Open Market | 7,000 | $389K | 11/13/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 5,000 | $19K | 8/7/2024 | View on chart |
| VCEL | ▼ Sell | Open Market | 5,000 | $230K | 8/7/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 2,000 | $7K | 8/7/2024 | View on chart |
| VCEL | ▼ Sell | Open Market | 2,000 | $92K | 8/7/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,200 | — | 5/1/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 2,600 | — | 4/27/2023 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 2,600 | — | 4/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Truist lowers Vericel price target to $52
Truist Securities maintained its positive stance on Vericel but reduced its price target to $52. This adjustment places the new target below the current average analyst estimate of $60.57. The move reflects a cautious outlook despite the firm's continued positive assessment of the company.
Truist lowers Vericel price target to $52. Truist Securities maintained its positive stance on Vericel but reduced its price target to $52. This adjustment places the new target below the current average analyst estimate of $60.57. The move reflects a cautious outlook despite the firm's continued positive assessment of the company.